Detail akcie Cartesian Rg online

Business Summary: Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cartesian Therapeutics Inc revenues decreased 95% to $1.9M. Net loss applicable to common stockholders decreased 40% to $40.4M. Revenues reflect Collaboration and license revenue decrease of 99% to $400K. Lower net loss reflects FV Adjustments of Financial Investments increase from $51.9M (expense) to $18.7M (income), Loss on change in fair value of forward decrease from $6.9M (expense) to $0K.